Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options, New Report Launched

Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts business intelligence provider Publisher.

According to the company’s latest report*, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

According to Senior Analyst, says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”

These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer’s palbociclib and neratinib, and Boehringer Ingelheim’s afatinib, will also contribute.

According to Senior Analyst continues: “The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.”

From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to Publisher.

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options report analyzes treatment usage patterns, market characterization, pipeline analysis, key licensing and co-development deals in the breast cancer therapeutics market in Australia, China, India and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

Know more about this report at: http://mrr.cm/ZNr

Find all Diseases Reports at : http://www.marketresearchreports.com/diseases